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The relative power of linkage and association studies for the detection
of genes involved in hypertension. Hypertension is a common disorder
that shows a polygenic mode of inheritance. Attempts to localize genes
involved in the disorder have been carried out using both linkage and
association tests. The relative merit of these two approaches is reviewed
with an assessment of their utility for detecting genes involved in
hypertension. Power calculations were carried out following the method of
Risch and Merikangas [1], assuming markers were typed across the
genome. These show that, if there is a single major locus causing
susceptibility, non-parametric linkage strategies using affected sibpairs
may well prove very effective. However, if there are a number of genes of
small effect, the sample size necessary for linkage studies will be prohib-
itive and a systematic search for allelic association may be more appro-
priate. This is due to the dramatic reduction in the excess allele sharing for
genes of small effect.
Many common disorders show complex patterns of inheritance.
This may be due in part to differences in environmental exposure,
however, in many cases this complex inheritance will be due to the
presence of a number of distinct susceptibility genes. Whether
these act independently or in an epistatic fashion will generally be
unknown. Because of this, the application of classical linkage
analysis that requires the specification of a model of the inheri-
tance is difficult. To circumvent these problems, non-parametric
methods of linkage analysis have been developed. Instead of
tracking the inheritance of a hypothesized (causative) disease
gene, these non-parametric methods examine which parts of the
genomes of a pair of affected relatives are identical by descent
(IBD) [2]. The most common paradigm uses affected sibling-pairs
and compares the IBD allele sharing at a given marker to the
expectation under the null hypothesis that no gene is present.
Thus, at a marker that is close to a susceptibility gene, it would be
expected that there would be an increase in the sharing in that
region with affected siblings sharing both alleles IBD more
frequently than sharing neither allele.
Risch developed a maximum likelihood method of estimating
the IBD sharing probability from sibling-pair data [3–5]. The
extent to which sharing deviates from the null depends on both
the magnitude of the genetic effect of the susceptibility gene to
which the marker is linked (here measured in terms of ls) and the
strength of that linkage (a function of the recombination fraction,
u). The lod score is then a function of this deviation and the
number of sibpairs used in the analysis. The expected deviation
from the null for a given u and ls provides an indication of the
power to detect susceptibility loci of different effect for maps of
different densities. Risch calculated these expected sharing prob-
abilities for a variety of different relative pairs (equations 8 to 22
in [4]). These depend not only on the relative recurrence risk in
siblings of affected individuals, but also on the recurrence risk in
offspring and monozygotic twins. By assuming that the dominance
variance (VD) is zero (that is, the phenotype of a heterozygote is
exactly intermediate to the phenotypes of the two different
homozygotes), the expected sharing probabilities may be ex-
pressed in terms of ls alone [4]. By imposing the condition of no
dominance variance, the probability of sharing one allele IBD for
a pair of siblings is fixed at 0.5. Consideration of either the deficit
in 0-sharing or the excess of 2-sharing will give an indication of the
overall deviation from the null hypothesis. The validity of this
assumption for hypertension is unclear. The restriction VD 5 0
implies that the recurrence risk in siblings is equal to the
recurrence risk in offspring of affected parents (ls 5 lo) [4].
Because blood pressure is a quantitative age-dependent trait,
determining these values (particularly lo) is difficult. However,
the correlation coefficients have been measured a number of
times and have been shown to take similar values for sibling and
parent-offspring comparisons ([6] and references therein). As
they are of comparable magnitude (0.12 to 0.43 for siblings, 0.12
to 0.37 for parent-offspring), qualitative predictions made under
the assumption of no dominance variance will probably be
acceptable.
Figure 1 shows the expected 2-sharing (IBD) for a pair of
siblings as function of the recombination fraction (u) between the
marker and the susceptibility gene and the magnitude of the
genetic effect associated with that particular gene (measured in
terms of ls). When recombination is zero (the marker is in perfect
linkage with the susceptibility gene) and the ls is high (;10), the
2-sharing approaches its maximum possible value (under the
assumption of no dominance variance) of 0.5. However, the
sharing declines rapidly as the recombination fraction increases,
taking the null value of 0.25 at u 5 0.5 irrespective of the
magnitude of ls.
Whereas the decline in allele sharing as a function of recombi-
nation is approximately linear, the reduction in 2-sharing as the ls
value decreases is initially less extreme. For values greater than 2
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the deviation is quite strong, whereas for values less than 2, the
sharing rapidly declines towards the null of 0.25. It is important to
note that the allele sharing may not always be unambiguously
scored, and the power to detect susceptibility genes will be further
decreased when there are missing data or low marker polymor-
phism. Clearly, the density of markers used in the study and their
polymorphism is critical to the power of the genome screen [7].
TRANSMISSION DISEQUILIBRIUM TEST
An alternative method of determining the location of a putative
disease gene is to look for allelic association. In sibling-pair
analysis, the interest is in whether the two affected individuals
shared the same allele at a given marker irrespective of which
particular allele is actually shared. For association studies, the
search is for the over representation of a specific allele in affected
individuals. In the simplest scenario, the frequency of alleles in a
population of affected individuals (cases) is compared to the
frequency in a normal (control) population. A positive result is
scored when there is an increased frequency of a particular allele
in the cases. The disadvantage of this method is that false positive
results can occur when the control population is not appropriately
matched to the cases. An alternative test was suggest by Spielman
et al [8], which used family based controls. This test requires the
collection of trios of two parents and an affected child. The
frequency at which alleles are transmitted and not-transmitted to
the affected offspring is compared to the Mendelian expectation
of 50:50. Importantly, this is a test for linkage disequilibrium
requiring the presence of both linkage and allelic association in
order to yield a significant result. By using the non-transmitted
alleles as the control population, problems of population admix-
ture and mismatched controls are avoided.
STATISTICAL POWER
When designing a genetic study, two factors must be consid-
ered: the acceptable false positive (type I) error rate and the false
negative (type II) error rate. False positives occur when a result is
considered to be statistically significant evidence for the presence
of a susceptibility gene even though the null hypothesis (no gene)
is true. A false negative result occurs when the null hypothesis is
accepted even though the gene is actually involved in the disorder.
A further complication arises from the fact that a large number of
genetic markers are being investigated, raising the problem of
multiple testing. For linkage analysis it was assumed that 500
markers were genotyped, whereas for association studies it was
assumed that 500,000 markers were studied. Given the typical
distance over which linkage and association usually extend, it was
further assumed that each of these tests was independent and a
correction was made accordingly. In all the power calculations it
was assumed that the genome-wide false positive rate was 5% and
the false negative rate was 20% (after Risch and Merikangas [1,
9]).
RESULTS
The sample size necessary to achieve a given statistical power is
dependent on both the magnitude of the genetic effect (ls), and
on the frequency of the susceptibility allele (p). These two factors
need not be independent. For example, a fully penetrant, caus-
ative allele will face much stronger selection pressure than an
allele that only results in a modest increase in the probability of
disease. As such, most likely it will have a lower frequency in the
general population. Table 1 shows that the frequency of the
susceptibility allele can dramatically affect the sample size. Be-
cause the allele frequencies will usually be unknown, accounting
for this in the design of experiments will be difficult.
When the ls for a particular susceptibility locus is small, the
number of individuals who must be typed for a classical sibling-
pair genome scan is far greater than the number required for an
association scan with the same power (Table 1). Thus, as was
asserted by Risch and Merikangas [1], association studies appear
to be more effective for detecting loci of moderate or small effect.
However, if the ls for a given locus is higher (say .2), this is no
longer always the case, with linkage studies usually requiring the
collection and genotyping of fewer families [10]. For example, if a
susceptibility gene has a ls of 1.5 and a population frequency of
1%, 338 sibling-pairs are required for a linkage screen to have an
80% probability of reaching the genome-wide 5% significance
Fig. 1. The expected identical by decent (IBD)
2-sharing for a pair of affected siblings as a
function of both the recombination fraction
between the disease susceptibility gene and the
marker and the ls of the susceptibility gene.
This was calculated under the assumption of no
dominance variance.
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level compared to 375 trios for a transmission disequilibrium test
(TDT) of equal power. Given the ls for hypertension is approx-
imately 3.5 [11], the relative merit of the two approaches depends
on whether the genetic effect is due to a single major locus or
spread across a number of different loci, possibly acting in an
epistatic manner. For a given disease, if the alleles at one
particular locus determine the majority of the genetic component
of susceptibility, then a screen for linkage may be the best
approach. However, if susceptibility is controlled by a number of
loci, screening for association may provide better results. In
insulin-dependent diabetes mellitus (IDDM), which has a ls of
about 10, a locus near the human leukocyte antigen (HLA) region
is a major determinate of susceptibility. This locus was easily
found in a linkage screen using approximately 100 sibling-pairs
[12]. Conversely, three whole-genome scans have been carried out
in multiple sclerosis (which shows much greater familial aggrega-
tion with a ls of between 20 and 50). Each of these studies used
approximately 100 sibling-pairs, yet none of them definitively
localized a major susceptibility locus [13–15]. For this disorder,
genome scans for linkage proved ineffective. In hypertension, a
large number of genetic studies have been carried out for both
linkage and association [reviewed in 16] with no single major locus
being found [17]. This suggests that the genetic basis of the
disease is controlled by a number of loci of modest effect, and
hence genome-wide scans for linkage will probably be ineffectual.
Whether a scan for association will prove more effective remains
uncertain as such an experiment is impractical using current
technology. When such technology does exist, the decision of
whether to search for linkage or association will become an
important issue.
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Table 1. The necessary sample size to detect a significant result (P ,
0.05) with 80% power for linkage analysis and TDT
g lS p
Linkage
(sibpairs)
TDT
(trios)
8 1.5 0.01 338 375
10.3 0.1 53 63
4 1.1 0.01 6400 1098
2.0 0.1 276 150
2 1.01 0.01 445838 5823
1.1 0.1 8085 695
1.5 1.002 0.01 6940000 19320
1.02 0.1 101897 2218
Abbreviations are: TDT, transmission disequilibrium test; p, the fre-
quency of the mutation; lS, the ratio of the recurrence risk in siblings to
the population risk; g, the genotype relative risk (after Risch & Merikan-
gas, 1996, 1997 [1,9]).
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